AlloVir (NASDAQ:ALVR) Trading Down 4.8% – Here’s What Happened

AlloVir, Inc. (NASDAQ:ALVR) fell 4.8% during mid-day trading on Tuesday . The stock traded as low as $6.58 and last traded at $6.88. 146,023 shares changed hands during trading, an increase of 811% from the average session volume of 16,030 shares. The stock had previously closed at $7.23.

AlloVir Trading Down 4.8 %

The stock’s fifty day simple moving average is $9.17 and its 200 day simple moving average is $12.04. The company has a market cap of $34.70 million, a price-to-earnings ratio of -0.34 and a beta of 0.63.

Hedge Funds Weigh In On AlloVir

A number of institutional investors have recently added to or reduced their stakes in ALVR. Raymond James Financial Inc. purchased a new position in AlloVir during the fourth quarter worth about $25,000. BNP Paribas Financial Markets purchased a new stake in shares of AlloVir during the 4th quarter valued at approximately $31,000. Jane Street Group LLC lifted its holdings in AlloVir by 47.8% in the fourth quarter. Jane Street Group LLC now owns 123,159 shares of the company’s stock valued at $52,000 after acquiring an additional 39,808 shares during the last quarter. Northern Trust Corp grew its position in AlloVir by 0.8% in the fourth quarter. Northern Trust Corp now owns 159,685 shares of the company’s stock worth $67,000 after acquiring an additional 1,267 shares during the period. Finally, Squarepoint Ops LLC acquired a new stake in AlloVir during the fourth quarter worth $142,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

AlloVir Company Profile

AlloVir, Inc engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.